These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 4539498)

  • 21. [Essential thrombocythemia: antiaggregants].
    Cortelazzo S; Barbui T
    Haematologica; 1991 Jun; 76 Suppl 3():371-3. PubMed ID: 1752535
    [No Abstract]   [Full Text] [Related]  

  • 22. Is hydroxyurea leukemogenic in essential thrombocythemia?
    Tefferi A
    Blood; 1998 Aug; 92(4):1459-60; author reply 1460-1. PubMed ID: 9694740
    [No Abstract]   [Full Text] [Related]  

  • 23. [Postextraction hemorrhage in patients with polycythemia vera].
    Nagy G; Gyulavári O
    Fogorv Sz; 1971 Dec; 64(12):450-3. PubMed ID: 5316694
    [No Abstract]   [Full Text] [Related]  

  • 24. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia.
    Elliott MA; Tefferi A
    Br J Haematol; 2005 Feb; 128(3):275-90. PubMed ID: 15667529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [23-year-old patient with abdominal pain, hepatosplenomegaly, ascites and leg edema].
    Oswald M; Beuers U; Pape GR; Paumgartner G
    Internist (Berl); 1995 Sep; 36(9):912-7. PubMed ID: 7591617
    [No Abstract]   [Full Text] [Related]  

  • 26. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis.
    Bucalossi A; Marotta G; Bigazzi C; Galieni P; Dispensa E
    Am J Hematol; 1996 May; 52(1):14-20. PubMed ID: 8638606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary thrombocythemia. Clinical, hematological and chromosomal studies of 13 patients.
    Frick PG
    Helv Med Acta; 1969 May; 35(1):20-9. PubMed ID: 5814492
    [No Abstract]   [Full Text] [Related]  

  • 28. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pipobroman (Vercyte) - a new antineoplastic drug.
    Med Lett Drugs Ther; 1967 Apr; 9(7):27. PubMed ID: 5298493
    [No Abstract]   [Full Text] [Related]  

  • 30. Thrombocythemia as a cause of oral hemorrhage.
    Pogrel MA
    Oral Surg Oral Med Oral Pathol; 1977 Oct; 44(4):535-8. PubMed ID: 302929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The dangers of surgery in uncontrolled haemorrhagic thrombocythaemia.
    Ravich RB; Gunz FW; Thompson IL; Reed CS
    Med J Aust; 1970 Apr; 1(14):704-8. PubMed ID: 5464014
    [No Abstract]   [Full Text] [Related]  

  • 32. [Familial Vaquez's diseases].
    Tursz T; Hakim J; Boivin P; Mallarmé J
    Presse Med (1893); 1971 Dec; 79(53):2427-32. PubMed ID: 5156526
    [No Abstract]   [Full Text] [Related]  

  • 33. [Some questions on the problem of thrombocythemia].
    Frinovskaia IV
    Probl Gematol Pereliv Krovi; 1968 Nov; 13(11):7-13. PubMed ID: 5753808
    [No Abstract]   [Full Text] [Related]  

  • 34. Busulfan versus hydroxyurea in the treatment of polycythemia vera (PV) and essential thrombocythemia (ET).
    Brodsky I
    Am J Clin Oncol; 1998 Feb; 21(1):105-6. PubMed ID: 9499248
    [No Abstract]   [Full Text] [Related]  

  • 35. "Secondary" thrombocythemia associated with chronic myelogenous leukemia and complicated by dental hemorrhage.
    Grubb J; Lucas J
    J Oral Surg; 1968 Jul; 26(7):453-6. PubMed ID: 5301391
    [No Abstract]   [Full Text] [Related]  

  • 36. Essential thrombocythemia following polycythemia vera: an unusual sequence.
    Randi ML; Barbone E; Zerbinati P; Soini B; Rossi C; Girolami A
    J Med; 1996; 27(5-6):363-8. PubMed ID: 9151204
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic and diagnostic value of endogenous erythroid colony formation in essential thrombocythemia.
    Ciaudo M; Hadjez JM; Teyssandier I; Coly E; Zittoun R; Marie JP
    Hematol Cell Ther; 1998 Aug; 40(4):171-4. PubMed ID: 9766922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug.
    Passamonti F; Cazzola M
    Haematologica; 2004 Nov; 89(11):1284. PubMed ID: 15531447
    [No Abstract]   [Full Text] [Related]  

  • 39. Metabolism of human prothrombin and fibrinogen in patients with thrombocytosis secondary to myeloproliferative states.
    Martinez J; Shapiro SS; Holburn RR
    Blood; 1973 Jul; 42(1):35-46. PubMed ID: 4736876
    [No Abstract]   [Full Text] [Related]  

  • 40. The management of elderly patients with myeloproliferative disorders.
    Tura S
    Hematol Oncol; 1993; 11 Suppl 1():39-41. PubMed ID: 8486340
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.